Xontogeny Leads $35M Series A Financing Round
Part of the capital will be used to advance TT-20, the company's candidate for the treatment of white matter brain injury in preterm infants.
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
